title: [Pharmacological and clinical profiles of a novel potassium-competitive acid blocker, vonoprazan fumarate (Takecab(®) 10 mg and 20 mg)].
authors.forename: Jun
authors.initials: J
authors.lastname: Matsukawa
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Inatomi
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Otake
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D011188:Potassium / Q000378:metabolism; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011758:Pyrroles / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D013272:Stomach Diseases / Q000188:drug therapy; D013449:Sulfonamides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*
chemical_list: C552956:1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; D026902:Potassium Channel Blockers; D011758:Pyrroles; D013449:Sulfonamides; D011188:Potassium